Personalis, Inc. (PSNL)
$15.85+0.32%Close
SELLBEAR · day 2
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.7B
- Beta
- 2.32
- P/E (TTM)
- -14.54
- Short % float
- 13.07%
- Days to cover
- 4.3
- SI change
- +1.9%
- 1W
- -1.12%
- 1M
- -2.70%
- vs SPY 1W
- -0.98%
- vs SPY 1M
- -5.21%
Industry peers
FMP comparable companies · ranked by market cap
- NTRABUYNatera, Inc.$57.4BBULLQ 30$400.71-0.53%
- GHSELLGuardant Health, Inc.$22.5BBEARQ 23$167.47-0.43%
- GRALBUYGRAIL Inc.$6.0BRECOVERYQ 68$140.58+2.17%
- BLLNSELLBillionToOne, Inc.$4.5BCRISISQ -9$98.09+1.47%
- VCYTBUYVeracyte, Inc.$3.6BBEARQ 14$45.23-2.07%
- WGSSELLGeneDx Holdings Corp.$2.0BCRISISQ -3$67.33+1.79%
- FLGTSELLFulgent Genetics, Inc.$617MRECOVERYQ 13$21.74-1.91%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
EARNINGS HISTORY
LOADING…Loading earnings…
Company news
FAQ
- What is LOPJLB’s current signal on PSNL?
- LOPJLB’s latest quantitative signal on Personalis, Inc. (PSNL) is SELL in a BEAR regime. Signals are updated daily.
- What market regime is PSNL in?
- Personalis, Inc. (PSNL) is currently classified in the BEAR HMM market regime on LOPJLB.
- What does Personalis, Inc. (PSNL) do?
- Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer treatments and facilitating extensive genetic research initiatives. Central to their offerings is the NeXT Platform, which enables detailed data analysis of tumors and their surrounding immune micr…